Archives
-
EZ Cap™ Firefly Luciferase mRNA (5-moUTP) Guide
2026-08-17
Learn how EZ Cap™ Firefly Luciferase mRNA (5-moUTP), SKU R1013, can improve reporter-based assessment of mRNA delivery, translation, and assay variability. This scenario-driven guide covers experimental design, handling, data interpretation, and practical product selection.
-
Sumatriptan Succinate: A Translational Playbook
2026-08-16
Sumatriptan is more than a clinically established migraine therapy: it is a mechanistically informative 5-HT1 receptor agonist for connecting serotonergic signaling, neurovascular biology, inflammation, and drug metabolism. This thought-leadership guide shows how translational researchers can use Sumatriptan Succinate to design stronger receptor, CGRP, inflammation, and biotransformation studies while avoiding common interpretation errors.
-
Oligo (dT) 25 Beads: Practical mRNA Purification
2026-08-15
Oligo (dT) 25 Beads provide a magnetic workflow for enriching polyadenylated eukaryotic mRNA from total RNA, cells, or animal and plant tissues. They are appropriate for polyA-selected mRNA workflows but should not be treated as a universal method for total RNA recovery or non-polyadenylated transcript isolation.
-
JHU-083 in Glutaminase Pathway Research
2026-08-14
JHU-083 is a 6-diazo-5-oxo-L-norleucine precursor described as a selective glutaminase antagonist for experimental cerebral malaria research. Its reported activity in cerebral CD11b cells makes it a useful neurological disease model compound for studying glutamate regulation and excitotoxicity.
-
PRMT5, Splicing, and Glutamine Dependence in Neuroblastoma
2026-08-14
The reference study shows that MYCN-amplified neuroblastoma is unusually vulnerable to PRMT5 inhibition because PRMT5 controls interconnected splicing, epitranscriptomic, and glutamine-metabolic programs. Its combination of transcriptomics, stable-isotope tracing, molecular validation, and mouse studies provides a mechanistic framework for cancer metabolism research and hypothesis-driven preclinical cancer drug evaluation.
-
Palonosetron for CINV: Evidence and Research Implications
2026-08-13
The reference review explains why palonosetron hydrochloride differs pharmacologically from earlier 5-HT3 receptor antagonists, emphasizing prolonged receptor engagement, allosteric binding, and positive cooperativity. Its clinical interpretation suggests a durable role in acute and delayed chemotherapy-induced nausea and vomiting prevention, while also highlighting the limits of cross-trial comparisons and nausea-focused endpoints.
-
AMPK–SQSTM1 Feedback Loop Under Metabolic Stress
2026-08-13
Cho et al. identify a double-positive feedback loop in which metabolic stress activates both AMPK and SQSTM1/p62, while AMPK activity reinforces p62 expression and phosphorylation. The mechanism connects lysosomal remodeling, TAK1-dependent p62 phosphorylation, KEAP1 degradation, and NRF2 activation, providing a framework for understanding antioxidant adaptation in STK11- and KEAP1-altered lung cancer.
-
E-64: From Cysteine Protease Tool to Immune Insight
2026-08-12
E-64 is an irreversible L-trans-epoxysuccinyl peptide that enables rigorous cysteine protease inhibition studies. This thought-leadership analysis connects its biochemical utility with cathepsin S biology, lymphoma antigen processing, experimental design, and translational decision-making.
-
Bradykinin BA5201: Vascular Assay Guide
2026-08-12
This guide explains how to handle Bradykinin (BA5201) as a controlled research stimulus for endothelial, vascular permeability, smooth muscle, pain, and inflammation assays. It is intended for scientific research only; solutions should be used promptly, and the product should not be used for diagnostic, therapeutic, or medical applications.
-
JHU-083 for Glutaminase Pathway Research
2026-08-11
JHU-083 is a 6-diazo-5-oxo-L-norleucine precursor designed for selective glutaminase pathway studies in cerebral CD11b cells and experimental cerebral malaria research. This workflow-focused guide shows how to connect glutamate measurements with redox, cell-identity, and disease-model readouts without confusing hepatic oxidative-stress evidence with direct neurological validation.
-
JHU-083: From Glutaminase Biology to Translation
2026-08-11
JHU-083 connects cell-selective glutaminase inhibition with glutamate biology in experimental cerebral malaria. This thought-leadership article outlines mechanistic rationale, validation workflows, redox hypotheses inspired by GSTA1 research, translational limitations, and strategic opportunities for neurological disease model development.
-
Hyperglycemia, Pin1/BRD4, and Gastric Cancer
2026-08-10
The reference study identifies a Pin1/BRD4 signaling axis through which high glucose promotes gastric carcinoma proliferation, cell-cycle progression, and migration. By combining cellular perturbation with tumor-growth and lung-metastasis models, it connects diabetic hyperglycemia to a testable cancer mechanism and highlights pathway inhibition as a potential experimental strategy.
-
IDH2, Ferroptosis, and TNBC Proliferation
2026-08-09
This study identifies wild-type IDH2 as a ferroptosis-associated regulator that supports triple-negative breast cancer proliferation. By integrating tumor datasets with clinical, cellular, and mouse-model validation, it connects redox metabolism to a potentially actionable vulnerability in TNBC and clarifies how DNA synthesis measurements can complement mechanistic studies.
-
Rice Stripe Virus NS3 Rewires Host Signaling
2026-08-08
Zhuang et al. show that Rice stripe virus NS3 switches between distinct functions during infection: early self-interaction suppresses antiviral RNA interference, whereas later phosphorylation and interaction with OsSnRK3.25 reshape ROS, programmed cell death, pathogenicity, and transmission. The study provides a mechanistic model of virus–plant–vector co-survival and highlights why infection stage and host context are essential experimental variables.
-
Sumatriptan Succinate in Translational Research
2026-08-07
Learn how to use Sumatriptan as a 5-HT1 receptor agonist across receptor, inflammation, metabolism, and neurovascular workflows. A pediatric emergency department study provides a clinically relevant framework for choosing route-aware assays, pain-related endpoints, and practical translational controls.